Air Pollution Exposure Impairs Airway Epithelium IFN-β Expression in Pre-School Children.

Introduction: Air pollution is a risk factor for respiratory infections and asthma exacerbations. We previously reported impaired Type-I and Type-III interferons (IFN-β/λ) from airway epithelial cells of preschool children with asthma and/or atopy. In this study we analyzed the association between rhinovirus-induced IFN-β/λ epithelial expression and acute exposure to the principal outdoor air pollutants in the same cohort.
Methods: We studied 34 children (17asthmatics/17non-asthmatics) undergoing fiberoptic bronchoscopy for clinical indications. Bronchial epithelial cells were harvested by brushing, cultured and experimentally infected with Rhinovirus Type 16 (RV16). RV16-induced IFN-β and λ expression was measured by quantitative real time PCR, as was RV16vRNA. The association between IFNs and the mean exposure to PM10, SO2 and NO ₂ in the day preceding bronchoscopy was evaluated using a Generalized Linear Model (GLM) with Gamma distribution.
Results: Acute exposure to PM10 and NO ₂ was negatively associated to RV16-induced IFNβ mRNA. For each increase of 1ug/m ³ of NO ₂ we found a significative decrease of 2.3x10 ³ IFN-β mRNA copies and for each increase of 1ug/m ³ of PM10 a significative decrease of 1x10 ³ IFN-β mRNA copies. No significant associations were detected between IFN-λ mRNA and NO ₂ nor PM10. Increasing levels of NO ₂ (but not PM10) were found to be associated to increased RV16 replication.
Conclusions: Short-term exposure to high levels of NO ₂ and PM10 is associated to a reduced IFN-β expression by the airway epithelium, which may lead to increased viral replication. These findings suggest a potential mechanism underlying the link between air pollution, viral infections and asthma exacerbations.
Competing Interests: MS reports grants from Chiesi Farmaceutici, grants from Laboratori Guidotti, grants from Bottega Veneta, grants from University of Padova- Italy, outside the submitted work. AP reports grants, personal fees, non-financial support and other from GlaxoSmithKline, grants, personal fees and non-financial support from AstraZeneca, grants, personal fees, non-financial support and other from Boehringer Ingelheim, grants, personal fees, non-financial support and other from Chiesi Farmaceutici, grants, personal fees, non-financial support and other from TEVA, personal fees, non-financial support and other from Mundipharma, personal fees, non-financial support and other from Zambon, personal fees, non-financial support and other from Novartis, grants, personal fees and non-financial support from Menarini, personal fees, non-financial support and other from Sanofi/Regeneron, personal fees from Roche, grants from Fondazione Maugeri, grants from Fondazione Chiesi, personal fees from Edmondpharma, outside the submitted work. MC reports grants, personal fees and non-financial support from Chiesi, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Alk-Abello, grants, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees and non-financial support from Zambon, grants from University of Ferrara - Italy, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Bonato, Gallo, Turrin, Bazzan, Baraldi, Saetta, Gregori, Papi, Contoli and Baraldo.)